Anebulo Pharmaceuticals, Inc. (ANEB) Cash Flow Statement
Where ANEB’s cash came from and went, FY2025
June 30, 2025 · U.S. dollars- Cash from operations
- −$6.3M
- Capital expenditures
- $3
- Free cash flow
- −$6.3M
- Returned to shareholders
- —
- Change in cash
- $8.5M cash at year-end $11.6M
Drawn to scale: where the cash came from and how it was used. Hover for values.
ANEB operating cash flow, capex and free cash flow
ANEB cash flow trends, FY2020–FY2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$150,772FY2020 | −$6.3MFY2025 | — | |
| Capital expenditures | $2FY2020 | $3FY2025 | +8.4%/yr | |
| Free cash flow | −$150,770FY2020 | −$6.3MFY2025 | — | |
| Stock-based compensation | $199,947FY2021 | $1.4MFY2025 | +64.0%/yr | |
| Share buybacks (net) | $0FY2020 | $0FY2021 | — |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
ANEB cash flow by activity
ANEB net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
ANEB cash flow statement
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|
| Operating activities | ||||||
| Net income | −$8.5M | −$8.2M | −$11.7M | −$6.8M | −$30.3M | −$174,637 |
| Depreciation & amortization | $382,014 | $151,230 | — | — | — | — |
| Stock-based compensation | $1.4M | $758,884 | $884,723 | $480,661 | $199,947 | — |
| Change in working capital | $306,238 | −$799,260 | $1.2M | $907,784 | −$1.4M | $22,579 |
| Other non-cash items | $0 | $0 | $0 | $0 | $26.6M | $1,286 |
| Cash from operating activities | −$6.3M | −$8.1M | −$9.7M | −$5.4M | −$4.9M | −$150,772 |
| Investing activities | ||||||
| Capital expenditures | −$3 | −$1 | $0 | −$4 | $0 | −$2 |
| Financing activities | ||||||
| Dividends paid | — | — | — | — | −$8.2M | — |
| Share repurchases & issuance (net) | — | — | — | — | $8.2M | $3.0M |
| Net borrowing (repayment) | — | — | — | $0 | −$201,286 | $1.2M |
| Shares issued | $15.0M | $0 | $6.6M | $6.6M | $22.9M | $0 |
| Other financing | −$116,664 | −$62,354 | −$264,683 | −$264,683 | −$821,630 | −$1.0M |
| Cash from financing activities | $14.9M | −$62,354 | $6.4M | $6.4M | $21.8M | $3.2M |
| Summary | ||||||
| Net change in cash | $8.5M | −$8.2M | −$3.3M | −$5.4M | $17.0M | $3.0M |
| Cash at end of period | $11.6M | $3.1M | $11.2M | $14.5M | $20.0M | $3.0M |
| Free cash flow | −$6.3M | −$8.1M | −$9.7M | −$5.4M | −$4.9M | −$150,770 |
| Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 | Mar '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$2.0M | −$2.2M | −$2.1M | −$1.7M | −$2.5M | −$2.2M | −$1.3M | −$1.7M | −$2.7M | −$2.5M | −$2.5M | −$2.8M |
| Depreciation & amortization | $34,879 | $17,440 | $17,439 | $245,182 | $59,696 | $59,697 | $151,230 | — | $31,838 | $2.5M | — | $2.9M |
| Stock-based compensation | $198,530 | $237,644 | $340,304 | $255,267 | $564,333 | $286,920 | $177,186 | $151,639 | $219,262 | $210,797 | $223,565 | $223,637 |
| Change in working capital | $470,225 | $630,194 | $135,033 | −$426,182 | $433,257 | $164,130 | −$939,852 | −$55,171 | $652,562 | −$456,799 | −$577,231 | $383,789 |
| Other non-cash items | −$17,440 | $0 | $0 | $0 | $0 | $0 | −$91,533 | $59,696 | $0 | −$2.5M | $0 | −$2.9M |
| Cash from operating activities | −$1.3M | −$1.3M | −$1.7M | −$1.6M | −$1.4M | −$1.7M | −$2.1M | −$1.5M | −$1.8M | −$2.7M | −$2.8M | −$2.2M |
| Investing activities | ||||||||||||
| Capital expenditures | $0 | $0 | $0 | $0 | −$4 | $0 | −$1 | $0 | −$3 | −$5 | −$4 | $0 |
| Financing activities | ||||||||||||
| Shares issued | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other financing | — | — | $0 | −$116,664 | $15.0M | — | $0 | $0 | −$62,354 | $0 | −$68,156 | −$68,156 |
| Cash from financing activities | — | — | $0 | −$116,664 | $15.0M | — | $0 | $0 | −$62,354 | $0 | −$68,156 | −$68,156 |
| Summary | ||||||||||||
| Net change in cash | −$1.3M | −$1.3M | −$1.7M | −$1.7M | $13.6M | −$1.7M | −$2.1M | −$1.5M | −$1.9M | −$2.7M | −$2.9M | −$2.2M |
| Cash at end of period | $9.0M | $10.4M | $11.6M | $13.3M | $15.0M | $1.4M | $3.1M | $5.1M | $6.6M | $8.5M | $11.2M | $14.2M |
| Free cash flow | −$1.3M | −$1.3M | −$1.7M | −$1.6M | −$1.4M | −$1.7M | −$2.1M | −$1.5M | −$1.8M | −$2.7M | −$2.8M | −$2.2M |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
ANEB cash generation
In fiscal 2025 (ended June 30, 2025), Anebulo Pharmaceuticals generated -$6.3 million of cash from operations and spent $0.0 million on capital expenditures, leaving free cash flow of -$6.3 million. Cash and equivalents rose by $8.5 million over the year.
Related: ANEB income statement, ANEB balance sheet. See the ANEB stock overview for the latest quote and news.
ANEB cash flow FAQ
What is Anebulo Pharmaceuticals's free cash flow?
Anebulo Pharmaceuticals's free cash flow was -$6.3 million in fiscal 2025: -$6.3 million of operating cash flow minus $0.0 million of capital expenditures It was -$8.1 million a year earlier..
How much cash does Anebulo Pharmaceuticals generate from operations?
Anebulo Pharmaceuticals generated -$6.3 million of cash from operating activities in fiscal 2025.
How much does Anebulo Pharmaceuticals spend on capital expenditures?
Anebulo Pharmaceuticals spent $0.0 million on capital expenditures in fiscal 2025, compared with $0.0 million the year before.